Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer’s disease mice

Shuta Ozawa,Yukiko Hori,Yusuke Shimizu,Atsuhiko Taniguchi,Takanobu Suzuki,Wenbo Wang,Yung Wen Chiu,Reiko Koike,Satoshi Yokoshima,Tohru Fukuyama,Sho Takatori,Youhei Sohma,Motomu Kanai,Taisuke Tomita
DOI: https://doi.org/10.1093/brain/awab058
IF: 14.5
2021-04-14
Brain
Abstract:Abstract Amyloid formation and the deposition of the amyloid-β peptide are hallmarks of Alzheimer’s disease pathogenesis. Immunotherapies using anti-amyloid-β antibodies have been highlighted as a promising approach for the prevention and treatment of Alzheimer’s disease by enhancing microglial clearance of amyloid-β peptide. However, the efficiency of antibody delivery into the brain is limited, and therefore an alternative strategy to facilitate the clearance of brain amyloid is needed. We previously developed an artificial photo-oxygenation system using a low molecular weight catalytic compound. The photocatalyst specifically attached oxygen atoms to amyloids upon irradiation with light, and successfully reduced the neurotoxicity of aggregated amyloid-β via inhibition of amyloid formation. However, the therapeutic effect and mode of actions of the photo-oxygenation system in vivo remained unclear. In this study, we demonstrate that photo-oxygenation facilitates the clearance of aggregated amyloid-β from the brains of living Alzheimer’s disease model mice, and enhances the microglial degradation of amyloid-β peptide. These results suggest that photo-oxygenation may represent a novel anti-amyloid-β strategy in Alzheimer’s disease, which is compatible with immunotherapy.
neurosciences,clinical neurology
What problem does this paper attempt to address?